NYSE:MYOV Myovant Sciences Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Myovant Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $22.60 +0.26 (+1.16 %) (As of 09/22/2020 12:00 AM ET) Add Compare Share Today's Range$22.05Now: $22.60▼$22.9850-Day Range$15.20MA: $19.00▼$22.3452-Week Range$4.14Now: $22.60▼$22.98Volume691,347 shsAverage Volume994,202 shsMarket Capitalization$2.04 billionP/E RatioN/ADividend YieldN/ABeta2.49 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction. Myovant Sciences Ltd. has partnership with Flo Health to create a digital tool to screen for heavy menstrual bleeding. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingMyovant Sciences has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.50, Myovant Sciences has a forecasted upside of 35.0% from its current price of $22.60.Amount of Analyst CoverageMyovant Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesMyovant Sciences has received 205 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMyovant Sciences has received 191 “underperform” votes. (Add your “underperform” vote.)Community SentimentMyovant Sciences has received 51.77% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Myovant Sciences and other stocks. Vote “Outperform” if you believe MYOV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MYOV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMyovant Sciences does not currently pay a dividend.Dividend GrowthMyovant Sciences does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Myovant Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,236,146.00 in company stock.Percentage Held by InsidersOnly 3.90% of the stock of Myovant Sciences is held by insiders.Percentage Held by Institutions35.63% of the stock of Myovant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Myovant Sciences are expected to remain at ($2.82) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Myovant Sciences is -7.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Myovant Sciences is -7.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.41 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:MYOV Previous SymbolNASDAQ:MYOV CUSIPN/A CIK1679082 Webwww.myovant.com Phone44-20-7400-3351Debt Debt-to-Equity RatioN/A Current Ratio2.07 Quick Ratio2.07Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.21) per share Price / Book-18.68Profitability EPS (Most Recent Fiscal Year)($3.37) Net Income$-288,990,000.00 Net MarginsN/A Return on Equity-2,288.94% Return on Assets-186.00%Miscellaneous Employees86 Outstanding Shares90,149,000Market Cap$2.04 billion Next Earnings Date11/10/2020 (Estimated) OptionableNot Optionable $22.60 +0.26 (+1.16 %) (As of 09/22/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MYOV News and Ratings via Email Sign-up to receive the latest news and ratings for MYOV and its competitors with MarketBeat's FREE daily newsletter. Myovant Sciences (NYSE:MYOV) Frequently Asked Questions How has Myovant Sciences' stock been impacted by Coronavirus? Myovant Sciences' stock was trading at $8.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MYOV shares have increased by 159.8% and is now trading at $22.60. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Myovant Sciences? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Myovant Sciences. When is Myovant Sciences' next earnings date? Myovant Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Myovant Sciences. How were Myovant Sciences' earnings last quarter? Myovant Sciences Ltd (NYSE:MYOV) posted its quarterly earnings data on Tuesday, August, 11th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.31. The business had revenue of $33.33 million for the quarter. View Myovant Sciences' earnings history. What price target have analysts set for MYOV? 7 brokerages have issued twelve-month price objectives for Myovant Sciences' shares. Their forecasts range from $20.00 to $55.00. On average, they anticipate Myovant Sciences' share price to reach $30.50 in the next year. This suggests a possible upside of 35.0% from the stock's current price. View analysts' price targets for Myovant Sciences. Are investors shorting Myovant Sciences? Myovant Sciences saw a decrease in short interest in the month of August. As of August 14th, there was short interest totaling 1,760,000 shares, a decrease of 13.3% from the July 30th total of 2,030,000 shares. Based on an average trading volume of 1,300,000 shares, the short-interest ratio is presently 1.4 days. Currently, 5.6% of the shares of the company are short sold. View Myovant Sciences' Short Interest. Who are some of Myovant Sciences' key competitors? Some companies that are related to Myovant Sciences include Jazz Pharmaceuticals (JAZZ), Mylan (MYL), Ascendis Pharma A/S (ASND), Mirati Therapeutics (MRTX), Ionis Pharmaceuticals (IONS), Myokardia (MYOK), ACADIA Pharmaceuticals (ACAD), Perrigo (PRGO), Bausch Health Companies (BHC), Emergent Biosolutions (EBS), Ultragenyx Pharmaceutical (RARE), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), United Therapeutics (UTHR) and Arrowhead Pharmaceuticals (ARWR). View all competitors. What other stocks do shareholders of Myovant Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Micron Technology (MU), Coty (COTY), VBI Vaccines (VBIV), NVIDIA (NVDA) and Carnival (CCL). Who are Myovant Sciences' key executives? Myovant Sciences' management team includes the following people: Dr. Lynn Seely, Principal Exec. Officer, Pres & Exec. Director (Age 60)Mr. Frank L. Karbe, Chief Financial Officer (Age 51)Mr. Matthew Lang, Gen. Counsel & Sec. (Age 43)Ms. Julie Tran MBA, MSHR, Sr. VP of HRMs. Marianne L. Romeo, Head of Global Transactions & Risk Management (Age 51) When did Myovant Sciences IPO? (MYOV) raised $176 million in an initial public offering (IPO) on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays served as the underwriters for the IPO and JMP Securities and Baird were co-managers. What is Myovant Sciences' stock symbol? Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV." Who are Myovant Sciences' major shareholders? Myovant Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Bellevue Group AG (5.16%), FMR LLC (3.20%), Cormorant Asset Management LP (2.77%), Victory Capital Management Inc. (2.10%), Opaleye Management Inc. (0.76%) and Platinum Investment Management Ltd. (0.34%). Company insiders that own Myovant Sciences stock include Andrew Lo, Chemical Co Ltd Sumitomo, Ferreira Juan Camilo Arjona, Frank Karbe, Kathleen Sebelius, Kim Sablich, Mark Altmeyer, Matthew Lang and Sciences Ltd Roivant. View institutional ownership trends for Myovant Sciences. Which institutional investors are selling Myovant Sciences stock? MYOV stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Ikarian Capital LLC, Bellevue Group AG, Cormorant Asset Management LP, Platinum Investment Management Ltd., Amia Capital LLP, Bank of America Corp DE, and Quantitative Systematic Strategies LLC. Company insiders that have sold Myovant Sciences company stock in the last year include Ferreira Juan Camilo Arjona, Frank Karbe, Kim Sablich, and Matthew Lang. View insider buying and selling activity for Myovant Sciences. Which institutional investors are buying Myovant Sciences stock? MYOV stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Gilder Gagnon Howe & Co. LLC, Rhenman & Partners Asset Management AB, Marshall Wace LLP, Candriam Luxembourg S.C.A., Barclays PLC, Marshall Wace North America L.P., and Synovus Financial Corp. Company insiders that have bought Myovant Sciences stock in the last two years include Andrew Lo, Chemical Co Ltd Sumitomo, Frank Karbe, Kathleen Sebelius, Mark Altmeyer, and Sciences Ltd Roivant. View insider buying and selling activity for Myovant Sciences. How do I buy shares of Myovant Sciences? Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Myovant Sciences' stock price today? One share of MYOV stock can currently be purchased for approximately $22.60. How big of a company is Myovant Sciences? Myovant Sciences has a market capitalization of $2.04 billion. The company earns $-288,990,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Myovant Sciences employs 86 workers across the globe. What is Myovant Sciences' official website? The official website for Myovant Sciences is www.myovant.com. How can I contact Myovant Sciences? Myovant Sciences' mailing address is 11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-7400-3351 or via email at [email protected] This page was last updated on 9/23/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
